It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
p97/VCP, an evolutionarily concerned ATPase, partakes in multiple cellular proteostatic processes, including the endoplasmic reticulum (ER)-associated protein degradation (ERAD). Elevated expression of p97 is common in many cancers and is often associated with poor survival. Here we report that the levels of p97 positively correlated with the histological grade, tumor size, and lymph node metastasis in breast cancers. We further examined p97 expression in the stem-like cancer cells or cancer stem cells (CSCs), a cell population that purportedly underscores cancer initiation, therapeutic resistance, and recurrence. We found that p97 was consistently at a higher level in the CD44+/CD24−, ALDH+, or PKH26+ CSC populations than the respective non-CSC populations in human breast cancer tissues and cancer cell lines and p97 expression also positively correlated with that of SOX2, another CSC marker. To assess the role of p97 in breast cancers, cancer proliferation, mammosphere, and orthotopic growth were analyzed. Similarly as p97 depletion, two pharmacological inhibitors, which targets the ER-associated p97 or globally inhibits p97’s ATPase activity, markedly reduced cancer growth and the CSC population. Importantly, depletion or inhibition of p97 greatly suppressed the proliferation of the ALDH+ CSCs and the CSC-enriched mammospheres, while exhibiting much less or insignificant inhibitory effects on the non-CSC cancer cells. Comparable phenotypes produced by blocking ERAD suggest that ER proteostasis is essential for the CSC integrity. Loss of p97 gravely activated the unfolded protein response (UPR) and modulated the expression of multiple stemness and pluripotency regulators, including C/EBPδ, c-MYC, SOX2, and SKP2, which collectively contributed to the demise of CSCs. In summary, p97 controls the breast CSC integrity through multiple targets, many of which directly affect cancer stemness and are induced by UPR activation. Our findings highlight the importance of p97 and ER proteostasis in CSC biology and anticancer therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Washington University School of Medicine, Division of Nephrology, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
2 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences, Department of Biochemistry, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
3 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); National Research Institute for Family Planning, Beijing, China (GRID:grid.453135.5) (ISNI:0000 0004 1769 3691)
4 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Patent Examination Corporation, State Intellectual Property Office, Chengdu, China (GRID:grid.473413.6) (ISNI:0000 0004 1798 910X)
5 Chinese Academy of Medical Sciences, Department of Biochemistry, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
6 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Tsinghua University, School of Pharmacy, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
7 Peking Union Medical College & Tsinghua University, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
8 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Shanxi Medical University, Department of Physiology, Taiyuan, China (GRID:grid.263452.4) (ISNI:0000 0004 1798 4018)
9 Chinese Academy of Medical Sciences, Department of Physiology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)